当前位置: 首页 >> 检索结果
701. Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.
作者: Benoit Lattuca.;Johanne Silvain.;Yan Yan.;Christophe Pouillot.;Thomas Cuisset.;Guillaume Cayla.;Patrick Henry.;Abdourahmane Diallo.;Simon Elhadad.;Grégoire Rangé.;Thibault Lhermusier.;Ziad Boueri.;Pascal Motreff.;Didier Carrié.;Eric Vicaut.;Gilles Montalescot.;Jean-Philippe Collet.
来源: Circ Cardiovasc Interv. 2019年12卷11期e007749页
In the ARCTIC trial (Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting), treatment adjustment following platelet function testing failed to improve clinical outcomes. However, high-on-treatment platelet reactivity (HPR) is considered as a predictor of poor ischemic outcome. This prespecified substudy evaluated clinical outcomes according to the residual platelet reactivity status after antiplatelet therapy adjustment.
702. Prosthetic Valve Endocarditis After TAVR and SAVR: Insights From the PARTNER Trials.
作者: Matthew R Summers.;Martin B Leon.;Craig R Smith.;Susheel K Kodali.;Vinod H Thourani.;Howard C Herrmann.;Raj R Makkar.;Philippe Pibarot.;John G Webb.;Jonathon Leipsic.;Maria C Alu.;Aaron Crowley.;Rebecca T Hahn.;Samir R Kapadia.;E Murat Tuzcu.;Lars Svensson.;Paul C Cremer.;Wael A Jaber.
来源: Circulation. 2019年140卷24期1984-1994页
Prosthetic valve endocarditis (PVE) is a rare but critical mechanism of valve failure and death after transcatheter and surgical aortic valve replacement (TAVR, SAVR) warranting further analysis in modern aortic valve replacement experience. We characterize the incidence, risk factors, microbiological profile and outcomes of PVE from the PARTNER trials and registries (Placement of Aortic Transcatheter Valve).
703. Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial.
作者: Jason G Andrade.;Jean Champagne.;Marc Dubuc.;Marc W Deyell.;Atul Verma.;Laurent Macle.;Peter Leong-Sit.;Paul Novak.;Mariano Badra-Verdu.;John Sapp.;Iqwal Mangat.;Clarence Khoo.;Christian Steinberg.;Matthew T Bennett.;Anthony S L Tang.;Paul Khairy.; .
来源: Circulation. 2019年140卷22期1779-1788页
Advanced generation ablation technologies have been developed to achieve more effective pulmonary vein isolation (PVI) and minimize arrhythmia recurrence after atrial fibrillation (AF) ablation.
704. Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combined Analysis of BRUISE CONTROL 1 and 2.
作者: Vidal Essebag.;Jeff S Healey.;Jacqueline Joza.;Pablo B Nery.;Eli Kalfon.;Tiago L L Leiria.;Atul Verma.;Felix Ayala-Paredes.;Benoit Coutu.;Glen L Sumner.;Giuliano Becker.;François Philippon.;John Eikelboom.;Roopinder K Sandhu.;John Sapp.;Richard Leather.;Derek Yung.;Bernard Thibault.;Christopher S Simpson.;Kamran Ahmad.;Satish Toal.;Marcio Sturmer.;Katherine Kavanagh.;Eugene Crystal.;George A Wells.;Andrew D Krahn.;David H Birnie.
来源: Circ Arrhythm Electrophysiol. 2019年12卷10期e007545页
Oral anticoagulant use is common among patients undergoing pacemaker or defibrillator surgery. BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial; NCT00800137) demonstrated that perioperative warfarin continuation reduced clinically significant hematomas (CSH) by 80% compared with heparin bridging (3.5% versus 16%). BRUISE-CONTROL-2 (NCT01675076) observed a similarly low risk of CSH when comparing continued versus interrupted direct oral anticoagulant (2.1% in both groups). Using patient level data from both trials, the current study aims to: (1) evaluate the effect of concomitant antiplatelet therapy on CSH, and (2) understand the relative risk of CSH in patients treated with direct oral anticoagulant versus continued warfarin.
705. Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial.
作者: Michel Zeitouni.;Olivier Barthélémy.;Marie Hauguel-Moreau.;Paul Guedeney.;Stéphanie Rouanet.;Georges Hage.;Pavel Overtchouk.;Delphine Brugier.;Nicolas Vignolles.;Mathieu Kerneis.;Johanne Silvain.;Jean-Philippe Collet.;Eric Vicaut.;Steffen Desch.;Uwe Zeymer.;Holger Thiele.;Gilles Montalescot.
来源: Circ Cardiovasc Interv. 2019年12卷10期e008296页 706. Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY).
作者: William B White.;Dorothy B Wakefield.;Nicola Moscufo.;Charles R G Guttmann.;Richard F Kaplan.;Richard W Bohannon.;Douglas Fellows.;Charles B Hall.;Leslie Wolfson.
来源: Circulation. 2019年140卷20期1626-1635页
Subcortical microvascular disease represented by brain white matter hyperintensity on magnetic resonance imaging is associated with functional decline in older people with hypertension. The effects of 2 levels of 24-hour average systolic blood pressure (BP) on mobility, white matter disease progression, and cognitive function over 3 years were studied.
707. Simulation-Based Mastery Learning Improves Patient and Caregiver Ventricular Assist Device Self-Care Skills: A Randomized Pilot Trial.
作者: Jeffrey H Barsuk.;Jane E Wilcox.;Elaine R Cohen.;Rebecca S Harap.;Kerry B Shanklin.;Kathleen L Grady.;Jane S Kim.;Gretchen P Nonog.;Lauren E Schulze.;Alison M Jirak.;Diane B Wayne.;Kenzie A Cameron.
来源: Circ Cardiovasc Qual Outcomes. 2019年12卷10期e005794页
No recognized standards exist for teaching patients and their caregivers ventricular assist device (VAD) self-care skills. We compared the effectiveness of a VAD simulation-based mastery learning (SBML) self-care training curriculum with usual VAD self-care training.
708. Electrical Stimulation of the Greater Auricular Nerve to Reduce Postoperative Atrial Fibrillation.
作者: Martin Andreas.;Philipp Arzl.;Andreas Mitterbauer.;Nicolas M Ballarini.;Frieda-Maria Kainz.;Alfred Kocher.;Guenther Laufer.;Michael Wolzt.
来源: Circ Arrhythm Electrophysiol. 2019年12卷10期e007711页
Postoperative atrial fibrillation (POAF) occurs in up to 40% of patients undergoing cardiac surgery. Invasive stimulation of the vagal nerve previously demonstrated a reduced risk of POAF. Therefore, we examined the antiarrhythmic and anti-inflammatory effects of noninvasive low-level transcutaneous electrical stimulation (LLTS) of the greater auricular nerve in a pilot trial including patients undergoing cardiac surgery.
709. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
作者: Brian A Bergmark.;Pieter W Kamphuisen.;Stephen D Wiviott.;Christian T Ruff.;Elliott M Antman.;Francesco Nordio.;Julia F Kuder.;Michele F Mercuri.;Hans J Lanz.;Eugene Braunwald.;Robert P Giugliano.
来源: Circulation. 2019年140卷22期1792-1801页
Numerous scales exist for the classification of major bleeding events. Limited data compare the most commonly used bleeding scales within a single at-risk cohort of patients with atrial fibrillation. Here, we analyze bleeding outcomes according to the ISTH (International Society on Thrombosis and Hemostasis), TIMI (Thrombolysis in Myocardial Infarction), GUSTO (Global Usage of Strategies to Open Occluded Arteries), and BARC (Bleeding Academic Research Consortium) bleeding scales in the ENGAGE AF (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation)-TIMI 48 trial (NCT00781391) of edoxaban versus warfarin.
710. Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial.
作者: Elizabeth A Magnuson.;Khaja Chinnakondepalli.;Katherine Vilain.;Clive Kearon.;Jim A Julian.;Susan R Kahn.;Samuel Z Goldhaber.;Michael R Jaff.;Andrei L Kindzelski.;Kevin Herman.;Paul S Brady.;Karun Sharma.;Carl M Black.;Suresh Vedantham.;David J Cohen.
来源: Circ Cardiovasc Qual Outcomes. 2019年12卷10期e005659页
In patients with acute deep vein thrombosis (DVT), pharmacomechanical catheter-directed thrombolysis (PCDT) in conjunction with anticoagulation therapy is increasingly used with the goal of preventing postthrombotic syndrome. Long-term costs and cost-effectiveness of these 2 treatment strategies from the perspective of the US healthcare system have not been compared.
711. High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction.
作者: Andrew R Chapman.;Philip D Adamson.;Anoop S V Shah.;Atul Anand.;Fiona E Strachan.;Amy V Ferry.;Kuan Ken Lee.;Colin Berry.;Iain Findlay.;Anne Cruikshank.;Alan Reid.;Alasdair Gray.;Paul O Collinson.;Fred Apple.;David A McAllister.;Donogh Maguire.;Keith A A Fox.;Catalina A Vallejos.;Catriona Keerie.;Christopher J Weir.;David E Newby.;Nicholas L Mills.; .
来源: Circulation. 2020年141卷3期161-171页
The introduction of more sensitive cardiac troponin assays has led to increased recognition of myocardial injury in acute illnesses other than acute coronary syndrome. The Universal Definition of Myocardial Infarction recommends high-sensitivity cardiac troponin testing and classification of patients with myocardial injury based on pathogenesis, but the clinical implications of implementing this guideline are not well understood.
712. Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial.
作者: Aman Kansal.;Zhen Huang.;Frank W Rockhold.;Iris Baumgartner.;Jeffrey S Berger.;Juuso I Blomster.;F Gerry Fowkes.;Brian Katona.;Kenneth W Mahaffey.;Lars Norgren.;William R Hiatt.;Manesh R Patel.;W Schuyler Jones.
来源: Circ Cardiovasc Interv. 2019年12卷10期e008069页
The relationship between invasive vascular procedures and bleeding in patients with peripheral artery disease has not been well described in the literature. This post hoc analysis from the EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease) aimed to describe the incidence of major and minor postprocedural bleeding and characterize the timing and severity of bleeding events relative to the procedure.
713. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
作者: Stephan Windecker.;Renato D Lopes.;Tyler Massaro.;Charlotte Jones-Burton.;Christopher B Granger.;Ronald Aronson.;Gretchen Heizer.;Shaun G Goodman.;Harald Darius.;W Schuyler Jones.;Michael Aschermann.;David Brieger.;Fernando Cura.;Thomas Engstrøm.;Viliam Fridrich.;Sigrun Halvorsen.;Kurt Huber.;Hyun-Jae Kang.;Jose L Leiva-Pons.;Basil S Lewis.;German Malaga.;Nicolas Meneveau.;Bela Merkely.;Davor Milicic.;João Morais.;Tatjana S Potpara.;Dimitar Raev.;Manel Sabaté.;Suzanne de Waha-Thiele.;Robert C Welsh.;Denis Xavier.;Roxana Mehran.;John H Alexander.; .
来源: Circulation. 2019年140卷23期1921-1932页
The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI.
714. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices.
作者: Kyungil Park.;Young-Rak Cho.;Jong-Sung Park.;Tae-Ho Park.;Moo-Hyun Kim.;Young-Dae Kim.
来源: Circ Cardiovasc Interv. 2019年12卷10期e008105页
Ticagrelor reduced the rate of myocardial infarction and death compared with clopidogrel in patients with acute coronary syndrome. However, little is understood about chronic treatment of ticagrelor on microvascular dysfunction. The objective of this study was to assess the impact of ticagrelor maintenance treatment on microvascular system and coronary flow in comparison with clopidogrel.
715. Angiographically Guided Complete Revascularization Versus Selective Stress Echocardiography-Guided Revascularization in Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Disease: The CROSS-AMI Randomized Clinical Trial.
作者: Ramón Calviño-Santos.;Rodrigo Estévez-Loureiro.;Jesús Peteiro-Vázquez.;Jorge Salgado-Fernández.;Alejandro Rodríguez-Vilela.;Raúl Franco-Gutiérrez.;Alberto Bouzas-Mosquera.;José Ángel Rodríguez-Fernández.;Alejandro Mesías-Prego.;Carlos González-Juanatey.;Guillermo Aldama-López.;Pablo Piñón-Esteban.;Xacobe Flores-Ríos.;Rita Soler-Martín.;Teresa Seoane-Pillado.;Nicolás Vázquez-González.;Javier Muñiz.;José Manuel Vázquez-Rodríguez.
来源: Circ Cardiovasc Interv. 2019年12卷10期e007924页
Recent trials suggest that complete revascularization in patients with acute ST-segment-elevation myocardial infarction and multivessel disease is associated with better outcomes than infarct-related artery (IRA)-only revascularization. There are different methods to select non-IRA lesions for revascularization procedures. We assessed the clinical outcomes of complete angiographically guided revascularization versus stress echocardiography-guided revascularization in patients with ST-segment-elevation myocardial infarction.
716. Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses: The Disrupt CAD II Study.
作者: Ziad A Ali.;Holger Nef.;Javier Escaned.;Nikos Werner.;Adrian P Banning.;Jonathan M Hill.;Bernard De Bruyne.;Matteo Montorfano.;Thierry Lefevre.;Gregg W Stone.;Aaron Crowley.;Mitsuaki Matsumura.;Akiko Maehara.;Alexandra J Lansky.;Jean Fajadet.;Carlo Di Mario.
来源: Circ Cardiovasc Interv. 2019年12卷10期e008434页
The feasibility of intravascular lithotripsy (IVL) for modification of severe coronary artery calcification (CAC) was demonstrated in the Disrupt CAD I study (Disrupt Coronary Artery Disease). We next sought to confirm the safety and effectiveness of IVL for these lesions.
717. Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial.
作者: Manel Sabaté.;Fernando Alfonso.;Angel Cequier.;Sebastián Romaní.;Pascual Bordes.;Antonio Serra.;Andrés Iñiguez.;Pablo Salinas.;Bruno García Del Blanco.;Javier Goicolea.;Rosana Hernández-Antolín.;Javier Cuesta.;Joan Antoni Gómez-Hospital.;Luis Ortega-Paz.;Josep Gomez-Lara.;Salvatore Brugaletta.
来源: Circulation. 2019年140卷23期1904-1916页
The use of poly-l-lactide acid-based bioresorbable scaffolds is limited in daily clinical practice because of safety concerns and lack of physiological benefit. Magnesium-based bioresorbable scaffold (MgBRS) presents a short resorption period (<1 year) and have the potential of being thromboresistant and exhibiting early restoration of vasomotor function. To date, however, no randomized clinical trial has investigated the performance of MgBRS. Therefore, this study aimed to compare the in-stent/scaffold vasomotion between MgBRS and permanent metallic sirolimus-eluting stent (SES) at 12-month follow-up in ST-segment-elevation myocardial infarction patients.
718. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial.
作者: Duk-Woo Park.;Osung Kwon.;Jae-Sik Jang.;Sung-Cheol Yun.;Hanbit Park.;Do-Yoon Kang.;Jung-Min Ahn.;Pil Hyung Lee.;Seung-Whan Lee.;Seong-Wook Park.;Si Wan Choi.;Sang-Gon Lee.;Hyuck-Jun Yoon.;Taehoon Ahn.;Moo Hyun Kim.;Deuk Young Nah.;Sung Yun Lee.;Jei Keon Chae.;Seung-Jung Park.; .
来源: Circulation. 2019年140卷23期1865-1877页
Owing to the differential propensity for bleeding and ischemic events with response to antiplatelet therapy, the safety and effectiveness of potent P2Y12 inhibitor ticagrelor in East Asian populations remain uncertain.
719. Effect of Transdermal Testosterone and Oral Progesterone on Drug-Induced QT Interval Lengthening in Older Men: A Randomized, Double-Blind, Placebo-Controlled Crossover-Design Study.
作者: Elena Tomaselli Muensterman.;Heather A Jaynes.;Kevin M Sowinski.;Brian R Overholser.;Changyu Shen.;Richard J Kovacs.;James E Tisdale.
来源: Circulation. 2019年140卷13期1127-1129页 720. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.
作者: Juan F Iglesias.;Dik Heg.;Marco Roffi.;David Tüller.;Stéphane Noble.;Olivier Muller.;Igal Moarof.;Stéphane Cook.;Daniel Weilenmann.;Christoph Kaiser.;Florim Cuculi.;Jonas Häner.;Peter Jüni.;Stephan Windecker.;Thomas Pilgrim.
来源: Circ Cardiovasc Interv. 2019年12卷8期e008024页
Randomized trials evaluating the Orsiro biodegradable polymer sirolimus-eluting stent (BP-SES; 60 and 80 μm strut thickness for stent diameters ≤3 and >3 mm, respectively) did not stratify according to vessel size and failed to specify the impact of ultrathin-strut thickness on long-term clinical outcomes compared with durable polymer everolimus-eluting stents (DP-EES). We sought to assess the long-term effect of ultrathin-strut (60 μm) BP-SES versus thin-strut (81 μm) DP-EES on long-term outcomes in patients undergoing percutaneous coronary revascularization for small vessel disease.
|